Latest Contract Wins And Expansions News

Acusensus Limited has raised its FY26 revenue guidance to $83-$87 million, driven by significant new contracts in the US and New Zealand and expansions in Australia. This upgrade signals strong momentum in the company’s AI-powered road safety enforcement business.

Resonance Health has revealed ambitious growth plans at its 2025 AGM, projecting revenue to nearly quadruple by FY26 while maintaining positive EBITDA guidance. The company is broadening its global footprint and diversifying its clinical trial services across multiple therapeutic areas.

Babylon Pump & Power reports a robust start to FY26 with strong rental segment growth and successful integration of two acquisitions, driving a $1.6 million net operating cash inflow.

Resonance Health reports robust FY25 results with 29% revenue growth and outlines ambitious FY26 guidance targeting $17 million in revenue and $2 million EBITDA. The company’s transformation into three profit-generating segments underpins its expanding footprint in the global clinical trial ecosystem.

Acusensus Limited reported a 20% increase in revenue to $59.35 million for FY25, driven by new and expanded contracts across Australia, New Zealand, the US, and the UK. However, net losses widened by 72.3%, reflecting higher operating expenses and ongoing litigation costs.

NEXTDC has expanded its senior debt facilities to A$6.4 billion, enhancing financial flexibility to support rapid expansion driven by record contract wins and rising demand for AI and cloud infrastructure.

Bioxyne Limited has reported record revenue and cash flow for FY25, driven by robust growth in the Australian medical cannabis market and strategic advances into Europe and the UK.

Acusensus has secured major contract expansions across Australia and New Zealand, driving a 15.8% revenue increase in Q2 FY25 and bolstering its cash reserves to $30.3 million. The company’s strategic international push and innovative enforcement technologies position it for sustained growth.